NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$94.08 +0.66 (+0.71 %)
(As of 05/24/2018 07:26 AM ET)
Previous Close$93.42
Today's Range$92.18 - $95.48
52-Week Range$41.76 - $95.48
Volume476,329 shs
Average Volume783,478 shs
Market Capitalization$8.40 billion
P/E Ratio-58.07
Dividend YieldN/A
Beta0.32

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Debt-to-Equity Ratio1.03
Current Ratio11.06
Quick Ratio11.06

Price-To-Earnings

Trailing P/E Ratio-58.07
Forward P/E Ratio-392.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$161.63 million
Price / Sales52.33
Cash FlowN/A
Price / CashN/A
Book Value$4.05 per share
Price / Book23.23

Profitability

EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins-45.56%
Return on Equity-29.67%
Return on Assets-13.46%

Miscellaneous

Employees400
Outstanding Shares89,900,000

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences (NASDAQ:NBIX) issued its quarterly earnings data on Monday, April, 30th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.18. The firm earned $71.08 million during the quarter, compared to analyst estimates of $65.17 million. Neurocrine Biosciences had a negative net margin of 45.56% and a negative return on equity of 29.67%. During the same period last year, the business earned ($0.90) EPS. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

13 brokers have issued twelve-month price targets for Neurocrine Biosciences' stock. Their predictions range from $79.00 to $120.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.7692 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 60)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 60)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 38)

Has Neurocrine Biosciences been receiving favorable news coverage?

Media stories about NBIX stock have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a news sentiment score of 0.19 on Accern's scale. They also gave news headlines about the company an impact score of 45.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.46%), BB Biotech AG (3.79%), Franklin Resources Inc. (2.62%), Artisan Partners Limited Partnership (2.19%), Wells Fargo & Company MN (1.06%) and OppenheimerFunds Inc. (0.93%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Neuberger Berman Group LLC, Dupont Capital Management Corp, DekaBank Deutsche Girozentrale, A.R.T. Advisors LLC, BB Biotech AG and Candriam Luxembourg S.C.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., BlackRock Inc., Rock Springs Capital Management LP, Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc. and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $94.08.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $8.40 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  639 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  774
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $102.7692, suggesting that the stock has a possible upside of 9.24%. The high price target for NBIX is $120.00 and the low price target for NBIX is $79.00. There are currently 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $102.7692$95.2308$91.50$78.8750
Price Target Upside: 9.24% upside24.13% upside7.12% upside5.67% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018OppenheimerSet Price TargetBuy$120.00LowView Rating Details
5/7/2018CowenReiterated RatingBuy$100.00LowView Rating Details
5/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$101.00 ➝ $102.00HighView Rating Details
5/1/2018Deutsche BankSet Price TargetBuy ➝ Buy$97.00 ➝ $99.00HighView Rating Details
5/1/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $103.00HighView Rating Details
5/1/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$84.00 ➝ $100.00HighView Rating Details
3/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$113.00MediumView Rating Details
2/22/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $110.00LowView Rating Details
2/20/2018Leerink SwannBoost Price TargetOutperform$90.00 ➝ $96.00MediumView Rating Details
2/14/2018BarclaysReiterated RatingOverweight$100.00HighView Rating Details
1/5/2018Jefferies GroupBoost Price TargetBuy$105.00MediumView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$83.00 ➝ $109.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 ➝ $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform ➝ OutperformN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2018 EPS Consensus Estimate: $0.06
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.28)($0.22)($0.26)
Q2 20184($0.17)$0.33($0.04)
Q3 20183$0.00$0.41$0.14
Q4 20184$0.01$0.51$0.21

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.11)N/AView Earnings Details
4/30/2018Q1 2018($0.29)($0.47)$65.17 million$71.08 millionViewListenView Earnings Details
2/13/2018Q4 2017$0.18$0.07$94.00 million$94.52 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.49)($0.13)$29.38 million$60.77 millionViewN/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.50)($0.46)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.2860)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
2/8/2012Q4 2011$0.01$0.02ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
10/28/2010Q3 2010$0.05$0.06ViewN/AView Earnings Details
7/28/2010Q2 2010($0.17)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.24)($0.20)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.28)($0.22)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.35)($0.21)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.41)($0.37)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.38)($0.38)ViewN/AView Earnings Details
2/3/2009Q4 2008($0.47)($0.75)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.52)($0.46)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.52)($0.55)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.54)($0.55)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.84)($0.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neurocrine Biosciences (NASDAQ:NBIX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/7/2018Corinne H NevinnyDirectorSell5,000$83.13$415,650.0043,283View SEC Filing  
5/1/2018Kevin Charles GormanCEOSell126,832$80.75$10,241,684.00473,865View SEC Filing  
3/5/2018Haig P BozigianInsiderSell75,873$90.00$6,828,570.0018,041View SEC Filing  
2/15/2018Gary A LyonsDirectorSell5,000$84.67$423,350.00View SEC Filing  
2/12/2018Dimitri E GrigoriadisInsiderSell86,368$78.32$6,764,341.76154,717View SEC Filing  
2/9/2018Dimitri E GrigoriadisInsiderSell71,775$77.98$5,597,014.50154,717View SEC Filing  
2/6/2018Kevin Charles GormanCEOSell105,983$80.25$8,505,135.75339,482View SEC Filing  
2/5/2018Gary A LyonsDirectorSell5,000$83.08$415,400.00267,066View SEC Filing  
2/5/2018Haig P BozigianInsiderSell2,262$83.10$187,972.2076,950View SEC Filing  
1/24/2018William H RastetterDirectorSell9,500$90.00$855,000.0034,250View SEC Filing  
1/16/2018Haig P BozigianInsiderSell1,625$79.12$128,570.00View SEC Filing  
1/16/2018Kevin Charles GormanCEOSell3,750$78.89$295,837.50View SEC Filing  
1/3/2018Darin LippoldtInsiderSell1,979$79.36$157,053.44View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.00View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.0028,394View SEC Filing  
12/8/2017Darin LippoldtInsiderSell2,955$75.00$221,625.0016,112View SEC Filing  
12/4/2017Darin LippoldtInsiderSell6,279$75.04$471,176.1619,436View SEC Filing  
12/1/2017Gary A LyonsDirectorSell10,000$72.92$729,200.00272,066View SEC Filing  
11/15/2017Darin LippoldtInsiderSell9,900$73.05$723,195.00View SEC Filing  
11/8/2017Dimitri E GrigoriadisInsiderSell30,000$74.58$2,237,400.0077,691View SEC Filing  
11/2/2017Kyle GanoInsiderSell24,818$71.05$1,763,318.9084,596View SEC Filing  
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.0055,898View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00144,601View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50101,790View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00123,045View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00154,601View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.0057,707View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00107,691View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.8017,997View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.0034,603View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00117,691View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97354,346View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.0088,246View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30129,805View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32332,913View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51115,756View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80250,542View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82137,961View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.0035,044View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75247,802View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.0025,000View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75114,704View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50244,677View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50134,824View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.5031,794View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00240,927View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.0030,044View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.009,000View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.0055,044View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.0025,555View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.0015,464View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.0080,044View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.4057,788View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00105,044View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75111,454View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00228,077View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00131,374View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25110,079View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00224,952View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50129,874View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25108,454View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50221,202View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50128,124View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00105,308View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00106,829View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00217,452View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00252,066View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.0077,058View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.0096,544View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50180,952View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.0097,874View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.0075,433View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00177,202View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.0096,124View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.0022,488View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.0094,794View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.9676,954View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.7596,124View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.701,000View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.0076,954View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.3596,124View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
 Brokerages Expect Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $86.98 Million Brokerages Expect Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $86.98 Million
www.americanbankingnews.com - May 22 at 4:16 AM
Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.15 Per ShareNeurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - May 20 at 9:37 AM
Neurocrine Biosciences (NBIX) Receives Consensus Recommendation of "Buy" from BrokeragesNeurocrine Biosciences (NBIX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 20 at 1:34 AM
Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to Strong-BuyNeurocrine Biosciences (NBIX) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - May 18 at 1:19 PM
FY2021 EPS Estimates for Neurocrine Biosciences Lifted by Oppenheimer (NBIX)FY2021 EPS Estimates for Neurocrine Biosciences Lifted by Oppenheimer (NBIX)
www.americanbankingnews.com - May 17 at 9:10 AM
Neurocrine Biosciences (NBIX) Raised to Strong-Buy at ValuEngineNeurocrine Biosciences (NBIX) Raised to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 15 at 11:34 AM
Oppenheimer Analysts Give Neurocrine Biosciences (NBIX) a $120.00 Price TargetOppenheimer Analysts Give Neurocrine Biosciences (NBIX) a $120.00 Price Target
www.americanbankingnews.com - May 14 at 12:42 PM
Noteworthy Friday Option Activity: NBIX, VZ, JELDNoteworthy Friday Option Activity: NBIX, VZ, JELD
www.nasdaq.com - May 11 at 5:23 PM
Neurocrine Biosciences (NBIX) Director Corinne H. Nevinny Sells 5,000 SharesNeurocrine Biosciences (NBIX) Director Corinne H. Nevinny Sells 5,000 Shares
www.americanbankingnews.com - May 9 at 7:53 PM
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare ConferenceNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 5:09 PM
Neurocrine Biosciences (NBIX) Upgraded to Buy at BidaskClubNeurocrine Biosciences (NBIX) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - May 9 at 10:36 AM
Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with AntipsychoticsNeurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
finance.yahoo.com - May 8 at 5:10 PM
Neurocrine Biosciences (NBIX) Rating Reiterated by CowenNeurocrine Biosciences (NBIX) Rating Reiterated by Cowen
www.americanbankingnews.com - May 7 at 9:30 PM
5 Stocks That Are Screaming Buys Right Now5 Stocks That Are Screaming Buys Right Now
www.thestreet.com - May 7 at 5:15 PM
Neurocrine Biosciences (NBIX) to Post Q2 2018 Earnings of ($0.17) Per Share, Zacks Investment Research ForecastsNeurocrine Biosciences (NBIX) to Post Q2 2018 Earnings of ($0.17) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 7 at 1:56 AM
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real ...Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real ...
www.prnewswire.com - May 4 at 8:41 AM
 Brokerages Expect Neurocrine Biosciences (NBIX) Will Post Quarterly Sales of $81.22 Million Brokerages Expect Neurocrine Biosciences (NBIX) Will Post Quarterly Sales of $81.22 Million
www.americanbankingnews.com - May 4 at 2:10 AM
Kevin Charles Gorman Sells 126,832 Shares of Neurocrine Biosciences (NBIX) StockKevin Charles Gorman Sells 126,832 Shares of Neurocrine Biosciences (NBIX) Stock
www.americanbankingnews.com - May 3 at 10:18 PM
NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future GrowthNBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
finance.yahoo.com - May 3 at 5:02 PM
Equities Analysts Offer Predictions for Neurocrine Biosciences Q2 2018 Earnings (NBIX)Equities Analysts Offer Predictions for Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - May 3 at 8:16 AM
Oppenheimer Weighs in on Neurocrine Biosciences Q2 2018 Earnings (NBIX)Oppenheimer Weighs in on Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - May 3 at 8:16 AM
Zacks: Analysts Expect Neurocrine Biosciences (NBIX) Will Announce Earnings of -$0.02 Per ShareZacks: Analysts Expect Neurocrine Biosciences (NBIX) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 2 at 9:58 PM
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual MeetingNeurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
finance.yahoo.com - May 2 at 5:12 PM
Oppenheimer Brokers Cut Earnings Estimates for Neurocrine Biosciences (NBIX)Oppenheimer Brokers Cut Earnings Estimates for Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - May 2 at 10:00 AM
FY2019 Earnings Estimate for Neurocrine Biosciences Issued By Jefferies Group (NBIX)FY2019 Earnings Estimate for Neurocrine Biosciences Issued By Jefferies Group (NBIX)
www.americanbankingnews.com - May 2 at 10:00 AM
Bank of America Increases Neurocrine Biosciences (NBIX) Price Target to $102.00Bank of America Increases Neurocrine Biosciences (NBIX) Price Target to $102.00
www.americanbankingnews.com - May 1 at 2:38 PM
Neurocrine Biosciences (NBIX) Given a $99.00 Price Target by Deutsche Bank AnalystsNeurocrine Biosciences (NBIX) Given a $99.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - May 1 at 1:28 PM
JPMorgan Chase Increases Neurocrine Biosciences (NBIX) Price Target to $103.00JPMorgan Chase Increases Neurocrine Biosciences (NBIX) Price Target to $103.00
www.americanbankingnews.com - May 1 at 10:42 AM
Neurocrine Biosciences (NBIX) Receives Outperform Rating from Robert W. BairdNeurocrine Biosciences (NBIX) Receives Outperform Rating from Robert W. Baird
www.americanbankingnews.com - May 1 at 9:40 AM
Neurocrine Biosciences (NBIX) CEO Kevin Gorman on Q1 2018 Results - Earnings Call TranscriptNeurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 8:50 AM
Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMTEdited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
finance.yahoo.com - May 1 at 8:50 AM
Neurocrine Biosciences (NBIX) Posts Quarterly  Earnings Results, Misses Estimates By $0.18 EPSNeurocrine Biosciences (NBIX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - May 1 at 8:31 AM
Neurocrine Biosciences misses by $0.16, beats on revenueNeurocrine Biosciences misses by $0.16, beats on revenue
seekingalpha.com - April 30 at 4:56 PM
Neurocrine: 1Q Earnings SnapshotNeurocrine: 1Q Earnings Snapshot
finance.yahoo.com - April 30 at 4:56 PM
Neurocrine Biosciences Reports First Quarter 2018 Financial ResultsNeurocrine Biosciences Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 4:56 PM
Neurocrine Biosciences (NBIX) Set to Announce Earnings on MondayNeurocrine Biosciences (NBIX) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 4:29 AM
AbbVie Presents New Investigational Data For ElagolixAbbVie Presents New Investigational Data For Elagolix
www.nasdaq.com - April 27 at 9:02 AM
Neurocrine Biosciences (NBIX) Highlights New Data Analyses Demonstrating INGREZZA Improved Tardive Dyskinesia ...Neurocrine Biosciences (NBIX) Highlights New Data Analyses Demonstrating INGREZZA Improved Tardive Dyskinesia ...
www.streetinsider.com - April 26 at 5:00 PM
How Neurocrine Biosciences Is Positioned ahead of 1Q18 EarningsHow Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
finance.yahoo.com - April 26 at 5:00 PM
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body RegionsNeurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
www.prnewswire.com - April 25 at 8:31 PM
Neurocrine Biosciences (NBIX) Given Average Rating of "Buy" by AnalystsNeurocrine Biosciences (NBIX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 1:34 AM
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results
finance.yahoo.com - April 23 at 4:56 PM
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ...Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ...
www.prnewswire.com - April 19 at 5:15 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ...SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ...
www.prnewswire.com - April 19 at 5:15 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 19 at 8:42 AM
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual MeetingNeurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 18 at 5:22 PM
 Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million
www.americanbankingnews.com - April 17 at 2:33 AM
Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per ShareNeurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 15 at 7:17 PM
Oppenheimer Comments on Neurocrine Biosciences Q2 2018 Earnings (NBIX)Oppenheimer Comments on Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - April 13 at 8:51 AM
Ingrezza: Boosting Neurocrine’s Top LineIngrezza: Boosting Neurocrine’s Top Line
finance.yahoo.com - April 12 at 5:10 PM

SEC Filings

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.